Zejula (Niraparib Tosylate) Patent Expiration, LOE Window & CMS Spending

Zejula (Niraparib Tosylate) by GSK: FDA Orange Book core substance LOE 2031-03-27 (last listed 2039-01-25), 0 AB generics, $260.1M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGSK
FDA Application & PathwayN214876 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2031-03-27
Last Listed Patent or Exclusivity Date2039-01-25
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$260.1M
2024 Medicare Part D Spend$224.1M
2024 Medicaid Spend$36.0M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 19.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.